Carlos Arteaga
Carlos L. Arteaga, M.D., was appointed Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center in Dallas in September 2017. Previously, he was the Associate Director for Clinical Research, director of the Center for Cancer Targeted Therapies, and professor of Cancer Biology and Medicine at Vanderbilt-Ingram Cancer Center. In 2014–2015, he was the president of the American Association for Cancer Research.Arteaga earned his medical degree from the Universidad de Guayaquil in Ecuador in 1980, where his father was the dean of medicine. He came to the United States intending to specialize in cardiology after his internal medicine residency at Emory University, but changed course and instead did a fellowship in hematology-oncology at University of Texas Health Science Center.
Arteaga joined the faculty at Vanderbilt in 1989 and since 2002, has directed the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE). Provided by Wikipedia
Showing 1 - 4 results of 4 for search 'Carlos L. Arteaga', query time: 0.01s
Refine Results
-
1
ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27 by Yong Wang, Yanan Wang, Lei Bao, Goncalo Vale, Jeffrey G. McDonald, Yisheng Fang, Yan Peng, Ashwani Kumar, Chao Xing, Fara Brasó-Maristany, Aleix Prat, Carlos L. Arteaga, Yingfei Wang, Weibo Luo
Published 2025-04-01Get full text
Article -
2
Publisher Correction: ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27 by Yong Wang, Yanan Wang, Lei Bao, Goncalo Vale, Jeffrey G. McDonald, Yisheng Fang, Yan Peng, Ashwani Kumar, Chao Xing, Fara Brasó-Maristany, Aleix Prat, Carlos L. Arteaga, Yingfei Wang, Weibo Luo
Published 2025-05-01Get full text
Article -
3
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial by Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Eileen Shimizu, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Published 2025-06-01Get full text
Article -
4
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context by Maxwell R. Lloyd, Rosario Chica-Parrado, Caroline M. Weipert, Todd C. Knepper, Emily L. Podany, Fabiana Napolitano, Dan Ye, Chang-Ching Lin, Yasuaki Uemoto, Jiemin Liao, Claire Wegrzyn, Christine M. Walko, Lianne Y. Ryan, Jennifer C. Keenan, Arielle J. Medford, Shiyuan A. Liu, Gerburg M. Wulf, Katherine K. Clifton, Cynthia X. Ma, Hyo S. Han, Nicole Zhang, Leif W. Ellisen, Aditya Bardia, Carlos L. Arteaga, Ariella B. Hanker, Seth A. Wander
Published 2025-08-01Get full text
Article